Literature DB >> 16012146

Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world.

Victoria G Hale1, Katherine Woo, Helene Levens Lipton.   

Abstract

Although some pharmaceutical company efforts to develop and distribute drugs in developing countries have been successful, many fall short of meeting needs in resource-poor nations. In the context of public-private partnerships, we discuss the concept of a nonprofit pharmaceutical company dedicated to developing and distributing drugs for diseases endemic in developing countries. Using the experience of the Institute for OneWorld Health, we present the vision, core elements of the product development model, and challenges confronting this model. Despite limitations, early successes raise hopes that a nonprofit drug company can exist successfully both as a global health organization and as a business.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16012146     DOI: 10.1377/hlthaff.24.4.1057

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  12 in total

1.  The societal benefit of nonprofit biotechnology companies.

Authors:  Rena M Conti
Journal:  Clin Adv Hematol Oncol       Date:  2008-05

2.  A global health elective course in a PharmD curriculum.

Authors:  Joyce Addo-Atuah; Arjun Dutta; Craig Kovera
Journal:  Am J Pharm Educ       Date:  2014-12-15       Impact factor: 2.047

Review 3.  Drug repurposing in oncology--patient and health systems opportunities.

Authors:  Francesco Bertolini; Vikas P Sukhatme; Gauthier Bouche
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

Review 4.  Non-profit Drug Research and Development at a Crossroads.

Authors:  Szymon Jarosławski; Mondher Toumi; Pascal Auquier; Claude Dussart
Journal:  Pharm Res       Date:  2018-02-07       Impact factor: 4.200

5.  Pharmacogenomic technologies: a necessary "luxury" for better global public health?

Authors:  Catherine Olivier; Bryn Williams-Jones
Journal:  Global Health       Date:  2011-08-24       Impact factor: 4.185

6.  Nonprofit biomedical companies.

Authors:  R M Conti; D O Meltzer; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2008-08       Impact factor: 6.875

Review 7.  Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system.

Authors:  Aaron S Kesselheim
Journal:  AAPS J       Date:  2007-08-03       Impact factor: 4.009

Review 8.  Affordable orphan drugs: a role for not-for-profit organizations.

Authors:  Elin H Davies; Emma Fulton; Daniel Brook; Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2017-02-08       Impact factor: 4.335

9.  The global health system: actors, norms, and expectations in transition.

Authors:  Nicole A Szlezák; Barry R Bloom; Dean T Jamison; Gerald T Keusch; Catherine M Michaud; Suerie Moon; William C Clark
Journal:  PLoS Med       Date:  2010-01-05       Impact factor: 11.069

10.  Distributed Drug Discovery, Part 1: linking academia and combinatorial chemistry to find drug leads for developing world diseases.

Authors:  William L Scott; Martin J O'Donnell
Journal:  J Comb Chem       Date:  2009 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.